https://scholars.lib.ntu.edu.tw/handle/123456789/638438
標題: | Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC | 作者: | Zhou, Qing Soo, Ross A Chang, Gee-Chen Chiu, Chao-Hua Hayashi, Hidetoshi Kim, Sang-We Teraoka, Shunsuke Goto, Yasushi Zhou, Jianying Ho-Fun Lee, Victor Kim, Dong-Wan Han, Baohui Chung Man Ho, James CHIA-CHI LIN Lu, Shun Polli, Anna Calella, Anna Maria Martini, Jean-François Wong, Chew Hooi Mok, Tony Kim, Hye Ryun Wu, Yi-Long |
關鍵字: | Anaplastic lymphoma kinase; Lorlatinib; Non–small cell lung cancer; Phase 3; Progression-free survival | 公開日期: | 五月-2023 | 卷: | 4 | 期: | 5 | 來源出版物: | JTO clinical and research reports | 摘要: | Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than crizotinib in patients with previously untreated, advanced, ALK-positive NSCLC. Here, we present a subgroup analysis of Asian patients in the CROWN study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638438 | ISSN: | 26663643 | DOI: | 10.1016/j.jtocrr.2023.100499 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。